Safety/efficacy of atezolizumab + bevacizumab during anti-platelet/anticoagulation therapy in unresectable hepatocellular carcinoma.
Michihisa MoriguchiKeiichiro OkudaGo HoriguchiSeita KataokaYuya SekoKanji YamaguchiTakeshi NishimuraHideki FujiiYasuhide MitsumotoMasami MiyagawaToshihiko KirishimaShinya OkishioTasuku HaraHiroki IshikawaYasuyuki NagaoMasayasu JoMichiaki IshiiSaiyu TanakaNorihito YamauchiHironori MitsuyoshiTomoki NakajimaHiroyoshi TaketaniKota YanoMasahiro AraiAtsushi UmemuraYoshito ItohPublished in: Liver international : official journal of the International Association for the Study of the Liver (2024)
Atezolizumab + bevacizumab therapy shows similar safety and efficacy in patients receiving and those not receiving anti-platelet agents or anticoagulants; therefore, it can be considered for patients with hepatocellular carcinoma receiving anti-platelet agents or anticoagulants.